Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

Scrip Asia 100 ebook

Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.


Spotlight On Earnings


Focus On Asia


Data Analysis


R&D


AstraZeneca ‘Playing To Win’ With Cardiometabolic Combinations

AstraZeneca ‘Playing To Win’ With Cardiometabolic Combinations

 

The UK-based company is playing catch up in obesity, but believes it has a unique offering in a three-in-one therapy now moving into Phase II.

Lazertinib’s US Approval A Catalyst For Oscotec’s Growth

Lazertinib’s US Approval A Catalyst For Oscotec’s Growth

 
• By 

Oscotec co-CEO Taeyoung Yoon highlights anti-resistance and anti-tau therapies as the Korean bioventure’s next possible blockbuster candidates after the landmark US approval of lazertinib for lung cancer.

Viking Excites With Latest Oral VK2735 Weight Loss Data

Viking Excites With Latest Oral VK2735 Weight Loss Data

 
• By 

Viking’s dual GLP-1/GIP agonist VK2735 continues to make headlines for strong efficacy and tolerability with oral and injectable formulations. CinFina reports progress with two new MOAs.

Roche Takes Its Time Before Joining Tricky Alzheimer’s Treatment Market

Roche Takes Its Time Before Joining Tricky Alzheimer’s Treatment Market

 

While Eisai/Biogen and Eli Lilly are focused on knocking down barriers to uptake for their anti-amyloid drugs, Roche hopes it can beat them both on safety and efficacy with its brain shuttle technology.

Business


Verona’s Ohtuvayre Off To Flying Start

Verona’s Ohtuvayre Off To Flying Start

 

Sales of its novel COPD therapy in its first quarter on the market were more than double consensus estimates, and Verona sees more to come.

Stock Watch: Sanofi’s Seasonal Surge And Novartis’s Material Write-Down

Stock Watch: Sanofi’s Seasonal Surge And Novartis’s Material Write-Down

 
• By 

Investors’ different responses to third-quarter sales growth at Sanofi and Novartis left future seasonal sales trends and past business development activity under scrutiny.

How To Speed Up MLR Reviews: A Master Class By J&J, UCB, ex-Takeda Heads

How To Speed Up MLR Reviews: A Master Class By J&J, UCB, ex-Takeda Heads

 
• By 

A panel of experts from J&J, UCB and Takeda deliberated on the use of AI and internal processes to strike the right balance between speed and accuracy in MLR reviews that could protect a company from serious repercussions

Novo Nordisk Taps Ascendis For Development Of A Once-Monthly GLP-1 Agonist

Novo Nordisk Taps Ascendis For Development Of A Once-Monthly GLP-1 Agonist

 
• By 

Deal Snapshot: Novo is partnering with Ascendis on less frequently dosed drugs for metabolic diseases, committing up to $285m for a lead program, a once-monthly GLP-1 receptor agonist.

Scrip Originals


Stock Watch: Sanofi’s Seasonal Surge And Novartis’s Material Write-Down

Stock Watch: Sanofi’s Seasonal Surge And Novartis’s Material Write-Down

 
• By 

Investors’ different responses to third-quarter sales growth at Sanofi and Novartis left future seasonal sales trends and past business development activity under scrutiny.

Pipeline Watch: Five Approvals And 15 Phase III Readouts

Pipeline Watch: Five Approvals And 15 Phase III Readouts

 
• By 

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Biogen Gets New Chief Medical Officer From BMS

Executives On The Move: Biogen Gets New Chief Medical Officer From BMS

 
• By 

Recent moves in the industry include changes at the top at Fennec Pharmaceuticals, plus Opthea Acquires Chief Financial Officer From Amarin, and Disc Medicine gets a new chief technical officer.

Finance Watch: Mega-Rounds Help 2024 Biopharma VC Funding Exceed 2023

Finance Watch: Mega-Rounds Help 2024 Biopharma VC Funding Exceed 2023

 
• By 

Private Company Edition: Despite a third quarter dip, venture capital investment in biopharma in 2024 is on track to beat 2023, new data confirm. VC mega-rounds of $100m or more helped boost the total, including recent financings totaling $175m for Alpha-9 and $112m for AvenCell.